280 related articles for article (PubMed ID: 22728157)
1. Brachytherapy provides comparable outcomes and improved cost-effectiveness in the treatment of low/intermediate prostate cancer.
Shah C; Lanni TB; Ghilezan MI; Gustafson GS; Marvin KS; Ye H; Vicini FA; Martinez AA
Brachytherapy; 2012; 11(6):441-5. PubMed ID: 22728157
[TBL] [Abstract][Full Text] [Related]
2. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
[TBL] [Abstract][Full Text] [Related]
3. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
4. High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer.
Martinez AA; Demanes J; Vargas C; Schour L; Ghilezan M; Gustafson GS
Am J Clin Oncol; 2010 Oct; 33(5):481-8. PubMed ID: 19952715
[TBL] [Abstract][Full Text] [Related]
5. Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.
Smith GD; Pickles T; Crook J; Martin AG; Vigneault E; Cury FL; Morris J; Catton C; Lukka H; Warner A; Yang Y; Rodrigues G
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):505-16. PubMed ID: 25596107
[TBL] [Abstract][Full Text] [Related]
6. Patterns of brachytherapy practice for patients with carcinoma of the cervix (1996-1999): a patterns of care study.
Erickson B; Eifel P; Moughan J; Rownd J; Iarocci T; Owen J
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1083-92. PubMed ID: 16099599
[TBL] [Abstract][Full Text] [Related]
7. Time-driven activity-based cost comparison of prostate cancer brachytherapy and intensity-modulated radiation therapy.
Dutta SW; Bauer-Nilsen K; Sanders JC; Trifiletti DM; Libby B; Lash DH; Lain M; Christodoulou D; Hodge C; Showalter TN
Brachytherapy; 2018; 17(3):556-563. PubMed ID: 29519605
[TBL] [Abstract][Full Text] [Related]
8. Low-dose-rate vs. high-dose-rate intracavitary brachytherapy for carcinoma of the cervix: The University of Alabama at Birmingham (UAB) experience.
Falkenberg E; Kim RY; Meleth S; De Los Santos J; Spencer S
Brachytherapy; 2006; 5(1):49-55. PubMed ID: 16563997
[TBL] [Abstract][Full Text] [Related]
9. Comparison of low and high dose rate brachytherapy in the treatment of uterine cervix cancer. Retrospective analysis of two sequential series.
Ferrigno R; Nishimoto IN; Novaes PE; Pellizzon AC; Maia MA; Fogarolli RC; Salvajoli JV
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1108-16. PubMed ID: 15990016
[TBL] [Abstract][Full Text] [Related]
10. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
11. Time-driven activity-based costing of low-dose-rate and high-dose-rate brachytherapy for low-risk prostate cancer.
Ilg AM; Laviana AA; Kamrava M; Veruttipong D; Steinberg M; Park SJ; Burke MA; Niedzwiecki D; Kupelian PA; Saigal C
Brachytherapy; 2016; 15(6):760-767. PubMed ID: 27720202
[TBL] [Abstract][Full Text] [Related]
12. LDR vs. HDR brachytherapy for localized prostate cancer: the view from radiobiological models.
King CR
Brachytherapy; 2002; 1(4):219-26. PubMed ID: 15062170
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of prostate boost with high-dose-rate brachytherapy versus intensity-modulated radiation therapy in the treatment of intermediate-high risk prostate cancer.
Vu CC; Blas KG; Lanni TB; Gustafson GS; Krauss DJ
Brachytherapy; 2018; 17(6):852-857. PubMed ID: 30076108
[TBL] [Abstract][Full Text] [Related]
14. After low and high dose-rate interstitial brachytherapy followed by IMRT radiotherapy for intermediate and high risk prostate cancer.
Nakamura S; Murakami N; Inaba K; Wakita A; Kobayashi K; Takahashi K; Okamoto H; Umezawa R; Morota M; Sumi M; Igaki H; Ito Y; Itami J
BMC Cancer; 2016 May; 16():296. PubMed ID: 27142069
[TBL] [Abstract][Full Text] [Related]
15. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
16. Health-related quality-of-life changes due to high-dose-rate brachytherapy, low-dose-rate brachytherapy, or intensity-modulated radiation therapy for prostate cancer.
Strom TJ; Cruz AA; Figura NB; Shrinath K; Nethers K; Mellon EA; Fernandez DC; Saini AS; Hunt DC; Heysek RV; Wilder RB
Brachytherapy; 2015; 14(6):818-25. PubMed ID: 26452602
[TBL] [Abstract][Full Text] [Related]
17. Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer.
Laviana AA; Ilg AM; Veruttipong D; Tan HJ; Burke MA; Niedzwiecki DR; Kupelian PA; King CR; Steinberg ML; Kundavaram CR; Kamrava M; Kaplan AL; Moriarity AK; Hsu W; Margolis DJ; Hu JC; Saigal CS
Cancer; 2016 Feb; 122(3):447-55. PubMed ID: 26524087
[TBL] [Abstract][Full Text] [Related]
18. [Clinical evaluation based on cost-effectiveness].
Inoue T; Inoue T
Gan To Kagaku Ryoho; 1998 Jan; 25(1):13-9. PubMed ID: 9464324
[TBL] [Abstract][Full Text] [Related]
19. Comparison of biologically equivalent dose-volume parameters for the treatment of prostate cancer with concomitant boost IMRT versus IMRT combined with brachytherapy.
Pieters BR; van de Kamer JB; van Herten YR; van Wieringen N; D'Olieslager GM; van der Heide UA; Koning CC
Radiother Oncol; 2008 Jul; 88(1):46-52. PubMed ID: 18378028
[TBL] [Abstract][Full Text] [Related]
20. Phase III randomized trial comparing LDR and HDR brachytherapy in treatment of cervical carcinoma.
Lertsanguansinchai P; Lertbutsayanukul C; Shotelersuk K; Khorprasert C; Rojpornpradit P; Chottetanaprasith T; Srisuthep A; Suriyapee S; Jumpangern C; Tresukosol D; Charoonsantikul C
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1424-31. PubMed ID: 15275728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
